Disease landscape
Lymphoma
A moderate level of restrictions in diagnosis and access to lymphoma treatment has been identified in the Visegrád (V4) countries as measured in the GAP score. Results vary from country to country and the difference between the highest and the lowest score is 25 points. The main reason for limited V4 performance is the constrained access to the registered drugs - including the novel drugs selected for detailed analysis - due to the lack of reimbursement or the high reimbursement restrictions.
Cross-Country
General GAP for Lymphoma
Compliance with guidelines
Positive recommendations for 9 lymphoma drugs were found in the clinical practice guidelines. From 5 to 7 of these are available to lymphoma patients in V4 countries. This indicates generally substantial limitations in the access to the latest treatments recommended in clinical practice guidelines, especially since the guidelines for lymphoma are relatively outdated.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
selected drugs
Drug access
Number of patientS treated
Drug access
Population treated (%)
Main issues
- The average time to reimbursement for lymphoma drugs in the V4 countries is 3.4 years. The difference between the shortest and the longest mean time to reimbursement among the states is 0.9 years.
- Podíl pacientů z cílové populace léčených analyzovanými vybranými novými léky je v zemích V4 nízký a odhaduje se na cca 35 % v roce 2021, s výjimkou Slovenska, které dosáhlo skóre 60 %.
- Disability adjusted life-years (DALY) burden in the V4 countries is about 10-15% lower than the EU average. As in the EU as a whole, the stabilization of burden was observed in the V4 countries in 2005-2019.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).